Intelligence · Clinical Pipeline
R&D Pipeline Programs
ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.
- Programs indexed
- 20,548
- Companies
- 1,769
- Drugs tracked
- 4,797
Quick answer
NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.
-
Firibastat
Quantum Biopharma
Hypertension
1 trial -
Firibastat (QGC001) Period 1
Quantum Biopharma
Hypertension (HTN)
1 trial -
The IMAGINE study: A phase 3b open label, single arm study to assess the effect of depemokimab on airway structure and function in asthma with Type 2 inflammation characterized by an eosinophilic phenotype utilizing quantitative high-resolution CT and bronchoscopic airway sampling in a sub study
GlaxoSmithKline
Asthma with type 2 inflammation characterized by an eosinophilic phenotype
1 trial -
Dendritic Cell Vaccination
Quantum Biopharma
Breast Cancer
1 trial -
FSD201
Quantum Biopharma
Mast Cell Activation Syndrome
1 trial -
FSD201
Quantum Biopharma
COVID-19
1 trial -
QGC001
Quantum Biopharma
Hypertension
1 trial -
QGC001
Quantum Biopharma
Heart Failure
1 trial -
QGC001
Quantum Biopharma
Essential Hypertension
1 trial -
Ramipril
Quantum Biopharma
Myocardial Infarction
1 trial -
A study to learn about how much emodepside gets absorbed in the blood and how food affects its absorption when given as a new type of tablet to healthy participants
Bayer AG
Onchocerciasis (river blindness): is an infectious disease caused by Onchocerca volvulus, a parasitic nematode worm. The disease is contracted through the bite of an infected blackfly of the genus Simulium, which transmits third-stage infective larvae. An estimated 18 million people suffer from onchocerciasis, with 99% cases in 31 African countries, and 187 million people at risk Onchocercal dermatitis is the most common symptom of the disease, but severe visual impairment and blindness are the most severe complication, and onchocerciasis is the world’s second-leading infectious cause of blindness. Programs for the treatment and control of onchocerciasis through mass drug administration of ivermectin have been in place for over 20 years. However, they require patients to be given treatment (ivermectin) at regular intervals for the life of the adult worm (up to 15 years), making implementation extremely difficult in endemic countries. Emodepside is a registered drug for animal health, marketed by Bayer Animal Health GmbH under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). It is a cyclooctadepsipeptide anthelmintic drug., Soil-transmitted helminth infection: Soil-transmitted helminthiasis is caused by one of the three soil-transmitted helminths (STH), Ascaris lumbricoides, Trichuris trichiura and hookworm (Ancylostoma duodenale and Necator americanus). Currently, STH still infects about 1.5 billion people worldwide, mostly in tropical and subtropical regions. Emodepside is a registered drug for animal health, marketed by Bayer Animal Health GmbH under the name of Profender® (in combination with praziquantel) or Procox® (in combination with toltrazuril). It is a cyclooctadepsipeptide anthelmintic drug.
1 trial -
Dendritic Cell Vaccination
Quantum Biopharma
Metastatic Breast Cancer
1 trial -
Dual-Wavelength Quantitative Fluorescence Endoscopy for Optical PD-1 and PD-L1 Imaging in Locally Advanced Esophageal Cancer: A Phase I Multicenter Feasibility and Safety Study
Disc Medicine
Esophageal cancer
1 trial -
Evaluating PD-1/PD-L1 in rectal cancer by quantitative fluorescence molecular endoscopy.
Disc Medicine
Locally advanced rectal cancer
1 trial -
Firibastat
Quantum Biopharma
Healthy Males
1 trial -
Lucid-21-302
Quantum Biopharma
Heathy Participants
1 trial -
Lucid-21-302
Quantum Biopharma
Healthy Participants
1 trial -
Optical PD-L1 imaging using Quantitative Fluorescence Endoscopy in locally advanced esophageal cancer using durvalumab-680LT: a phase I multicenter feasibility and safety study
Disc Medicine
Esophageal cancer
1 trial -
QGC001 [(3S,3'S)-4,4'-dithiobis (3-aminobutane-1-sulfonic acid)]
Quantum Biopharma
Essential Hypertension
2 trials -
firibastat
Quantum Biopharma
Healthy Volunteers
1 trial -
Pharmacist Practice Change to Dispense Appropriate Opioid Quantities for Acute Pain
BRIGHT MINDS BIOSCIENCES INC.
Opioid Use
1 trial -
FSD-F2R6-A-CP
Quantum Biopharma
Acute Alcohol Intoxication
1 trial -
Medium-quantity lipid-based nutrient supplement (MQ-LNS)
United Therapeutics Europe Ltd
Undernutrition
1 trial -
New Infant Cereal
Quantum Biopharma
Infant Nutrition Sciences
1 trial
Frequently asked questions
What is the NovaPharmaNews pipeline directory?
It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.
Where does pipeline data come from?
Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.
How do I find pipeline programs by company or phase?
Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.
Data attribution and licensing: Data sources